← Back to Search

Other

ANG-3070 for Proteinuria

Phase 2
Waitlist Available
Research Sponsored by Angion Biomedica Corp
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 12
Awards & highlights

Study Summary

This trial is testing a new drug to see if it is safe and effective in treating patients with a primary glomerular disease who have persistent proteinuria.

Eligible Conditions
  • Proteinuria
  • Glomerulonephritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage change in 24-hour urinary protein excretion at Week 12

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: 400 mg QDExperimental Treatment1 Intervention
400 mg of ANG-3070 will be taken once daily for 12 weeks
Group II: 300 mg BIDExperimental Treatment1 Intervention
300 mg of ANG-3070 will be taken twice a day for 12 weeks.
Group III: 200 mg QDExperimental Treatment1 Intervention
200 mg of ANG-3070 will be taken once daily for 12 weeks.
Group IV: PlaceboPlacebo Group1 Intervention
Placebo capsules will be taken once or twice daily for 12 weeks.

Find a Location

Who is running the clinical trial?

Angion Biomedica CorpLead Sponsor
11 Previous Clinical Trials
862 Total Patients Enrolled
John Neylan, MDStudy DirectorAngion Biomedica
3 Previous Clinical Trials
628 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any current opportunities for enrolling in this investigation?

"Indeed, the clinical trials platform indicates that this research is still recruiting participants. The project was created on December 24th 2021 and its requirements were last adjusted on March 22nd 2022. To date, 100 subjects are yet to be enrolled at 18 different sites."

Answered by AI

What is the geographic scope of this clinical experiment?

"This trial is being conducted at Amicis Research Center in Northridge, CA; University of Pennsylvania in Philadelphia, PA; The Johns Hopkins Hospital in Baltimore, MD and 18 other medical centres."

Answered by AI

How many individuals have enrolled in this study thus far?

"Affirmative. Clinical trials data on clinicaltrials.gov reveals that this investigation is actively recruiting participants, having first been posted to the site on December 24th 2021 and last updated on March 22nd 2022. A total of 100 patients need to be enrolled across 18 different medical sites."

Answered by AI

Has the federal agency sanctioned ANG-3070 for medical use?

"The safety of ANG-3070 is estimated to be a 2 on the scale, as this Phase 2 trial has only collected limited data regarding its efficacy. However, there is evidence to suggest it can be safely administered."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease
2021. "Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04939116.
All > Chronic Kidney Disease
~31 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top